Weekly Digest - 29 Apr-05 May 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 29 Apr-05 May 2023
May 03, 2023: Elahere / FRα-Positive Platinum-Resistant Ovarian Cancer / Immunogen: Phase 3 MIRASOL trial demonstrated improved clinical benefits
Immunogen announced positive top-line data from the Phase 3 confirmatory MIRASOL evaluating Elahere in comparison to Chemo for the treatment of FRα-positive platinum-resistant ovarian cancer with prior one to three prior lines of therapy
Statistically significant improvements in PFS, ORR, and OS compared to chemotherapy were observed
Median OS: 16.46 months vs 12.75 mont
Median PFS: 5.62 months vs 3.98 months
ORR: 42.3% vs 15.9%
No new safety signals were identified
- Grade 3 or greater TEAEs: 42% vs 54%
- Elahere is the first medicine to demonstrate an overall survival advantage in platinum-resistant ovarian cancer
- Submission of MAA in Europe and sBLA in the US anticipated in H2 2023
